You are here

Kronik Böbrek Yetmezliğinde Oksidatif Stres ve "Biyomarkır'ları

Oxidative Stress and "Biomarker"s in Chronic Renal Failure

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
Oxidative stress is one of the proposed mechanisms to explain renal function impairment in chronic renal failure (CRF). There is growing evidence supporting that oxidative balance is disturbed due to either overproduction of free radicals or insufficient antioxidant defense system in patients with end stage renal disease. Moreover, dialysis processes is accepted as a model for oxidative stress. In recent years, neutrophil-myeloperoxidase-hypochlorous acid mediated reactions suggest, as the main source of oxidative stress seen in CRF and these reactions seem directly to be related to inflammation. In the present review, the occurrence of oxidative stress and especially the oxidative modification mechanisms of proteins as well as oxidation products used as biomarkers are surveyed in CRF.
Abstract (Original Language): 
Kronik böbrek yetmezliğinde (KBY) ilerleyici fonksiyon kaybını açıklamak üzere öne sürülen mekanizmalardan biri de oksidatif strestir. Son dönem böbrek yetmezliği hastalarında, serbest radikallerin aşırı üretimi ya da yetersiz antioksidan savunma sistemi nedeniyle, oksidatif dengenin bozulduğuna dair görüşler giderek önem kazanmakta, hatta diyaliz ortamı oksidatif stres için bir model olarak düşünülmektedir. Son yıllarda nötrofil-miyeloperoksidaz-hipoklorik asit aracılı reaksiyonlar, KBY'de gözlenen oksidatif stresin başlıca kaynağı olarak kabul edilmekte ve bu oksidatif reaksiyonlar, doğrudan inflamasyonla ilişkili görünmektedir. Bu derlemede, KBY'de oksidatif stres oluşumu ve özellikle proteinlerin oksidatif modifikasyonuna neden olan mekanizmalar ile "biyo-markır" olarak kullanılan oksidatif ürünler gözden geçirilecektir.
FULL TEXT (PDF): 

REFERENCES

References: 

1.
Akpola
t T, Utaş C. Hemodiyaliz Hekimi El Kitabı. Kayseri, Anadolu Yayıncılık, 2001.
2. England BK, Mitch WE. Mechanisms of progression of renal insufficiency. In: Massry SG, Glassock RJ (eds), Textbook of Nephrology. 3rd ed, Volume 2. Baltimore, Williams and Wilkins, 1995: 1261-1269.
3. Heinzelmann M, Mercer-Jones MA, Passmore JC. Neutrophils and renal failure. Am J Kidney Dis 1999; 34:384-399.
4. Sies H. Oxidative stress: Oxidants and antioxidants. Exp Physiol 1997; 82:291-295.
5. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. Advan¬ced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49:1304-1313.
6. Amore A, Coppo R. Immunological basis of inflammation in di¬alysis. Nephrol Dial Transplant 2002; 17 (Suppl 8):S16-S24.
7. Descamps-Latscha B, Drüeke T, Witko-Sarsat V. Dialysis-induced oxidative stress: Biological aspects, clinical consequences, and therapy. Semin Dial 2001;14:193-199.
8. Sarpkaya
S
. Kronik Böbrek Yetmezliğinde Protein Oksidasyonu. Yüksek Lisans Tezi, Erciyes Üniversitesi Sağlık Bilimleri Enstitü¬sü, Kayseri 2003, ss 68.
9. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW. Myelo-peroxidase-catalyzed 3-chlorotyrosine formation in dialysis pati¬ents. Free Radic Biol Med 2001; 3:1163-1169.
10. Mimic-Oka J, Simic T, Pljesa M, Stupar N, Turkovic S. Oxidative modifications of plasma proteins in different stages of chronic re¬nal failure. Med Biol 2001; 8:1-5.
11. Weiss SL. Tissue destruction by neutrophils. N Eng J Med 1989;
320:365-376.
12. Paul JL. Influence of uremia on polymorphonuclear leukocytes oxidative metabolism in end-stage renal disease and dialyzed pa¬tients. Nephron 1991; 57:428-432.
13. Hörl HW, Riegel W, Schollmeyer P. Different complement and granulocyte activation in patient dialyzed with PMMA dialyzers. Clin Nephrol 1986; 25:304-307.
14. Höllgren R, Venge P, Danielson BG. Neutrophil and eosinophil degranulation during hemodialysis are mediated by the dialysis membrane. Nephron 1982; 32:329-334.
15. Hörl WH, Riegel W, Steinhauer HB, et al. Granulocyte activation during hemodialysis. Clin Nephrol 1986; 26:30-34.
16. Kuwahara T, Maskert M, Wauters JP. Neutrophil oxygen radical production by dialysis membranes. Nephrol Dial Transplant 1988; 3:661-665.
17. Chen MF, Chang CL, Liou SY. Increase in resting levels of supe-roxide anion in the whole blood of uremic patients on chronic hemodialysis. Blood Purif 1998; 16:290-300.
18. Gündüz Z, Düşünsel R, Köse K, Utaş C, Doğan P. The effect of di-alyzer reuse on plasma antioxidative mechanisms in patients on re¬gular hemodialysis treatment. Free Radic Biol Med 1996; 21: 225-231.
19. Hörl WH, Feinstein EL, Wanner C, et al. Plasma levels of main glanulocyte components during hemodialysis: comparison of new and reused dialyzers. Am J Nephrol 1990; 10:53-57.
20. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Pro¬tein carbonyl groups as biomarkers of oxidative stress. Clin Chim
Acta 2003; 329:23-38.
21. Massy ZA, Nguyen-Khoa T, Beauvais CH. Oxidative stress and chronic renal failure: markers and management. J Nephrol 2002; 15:336-341.
22. Miyata T, Sugiyama S, Saito A, Kurokawa K. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int
2001; 59:25-31.
23. Davies MJ, Fu S, Wang H, Dean RT. Stable markers of oxidant da¬mage to proteins and their application in the study of human di¬sease. Free Radic Biol Med 1999; 27:1151-1163.
24. Dean RT, Fu S, Stocker R, Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997; 324:1-18.
25. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxi¬dation in aging and disease. Chem Res Toxicol 1997; 10:485-494.
26. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic comp¬lications. Diabetes 1999; 48:1-8.
27. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney
Int 2000; 58:2571-2578.
28. Donate T, Herreros A, Martinez E, et al. Protein oxidative stress
in dialysis patients. Adv Perit Dial 2002; 18:15-17.
29. Sarpkaya
S
, Köse K, Yazıcı C, Utaş C. Kronik böbrek yetmezliğin¬de protein oksidasyonu. Erciyes Üniversitesi Sağlık Bilimleri Ens¬titüsü Dergisi 2003; 12:42-48.
30. Himmelfarb J, McMonagle E. Albumin is the major plasma prote¬in target of oxidant stress in uremia. Kidney Int 2001; 60:358-363.
31. Körmöczi GF, Wölfel UM, Rosenkranz AR, et al. Serum proteins modified by neutrophil-derived oxidants as mediators of neutrop-hil stimulation. J Immunol 2001; 167:451-460.
32. Miyata T, Strihou CY, Kurokawa K, Baynes JW. Alterations in no-nenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int
1999; 55:389-399.
33. Kumano K, Yokota S, Go M, et al. Quantitative and qualitative changes of serum albumin in CAPD patients. Adv Perit Dial 1992;
8:127-130.
34. Lameire N, Vanholder R, De Smet R. Uremic toxins and peritone¬al dialysis. Kidney Int 2001; 59:292-297.
35. Friedlander MA, Yu Ching W, Elgawish A, Monnier VM. Early and advanced glycosylation end products kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 1996; 97:728-735.
36. Erdoğan C, Ünlüçerçi Y, Türkmen A, et al. The evaluation of oxi-dative stress in patients with chronic renal failure. Clin Chim Ac-
ta 2002; 322:157-161.
37. Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 2001; 59
(Suppl.78):S108-S113.
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
123
9 Oxidative Stress and "Biomarker"s in Chronic Renal Failure
38. Nguyen-Khoa T, Massy ZA, De Bandt PJ, Kebede M, Salama L.
Oxidative stress and hemodialysis: role of inflammation and du¬ration of dialysis treatment. Nephrol Dial Transplant 2001; 16:
335-340.
39. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;
161:2524-2532.
40. Wayner DDM, Burton GW, Ingold KU, Barclay LRC, The relative
contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blo¬od plasma. Biochim Biophys Acta 1987; 924:408-419.
41. Hu ML, Locie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab
Clin Med 1993; 121:257-262.
42. Wlodek PJ, Iciek MB, Milkowski A, Smolenski OB. Various forms of plasma sistein and its metabolities in patients undergoing he-
modialysis. Clin Chim 2001; 304:9-18.
43. Prior RL, Cao G. In vivo total antioxidant capacity: Comparison of different analytical methods. Free Radic Biol Med 1999; 27:
1173-1181.
44. Kuroda M, Asaka S, Tofuku Y, Takeda R. Serum antioxidant acti¬vity in uremic patients. Nephron 1985; 41:293-298.
45. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidant in patients with chronic renal failure. Clin Chem 1995;
41:1135-1138.
46. Clermont G, Lecour S, Lahet JJ, et al. Alteration in plasma antioxi-dant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 2000; 47:618-623.
47. Bergesio F, Monzani G, Ciuti R, et al. Total antioxidant capacity (TAC): is it an effective method to evaluate the oxidative stress in uraemia. J Biolumin Chemilumin 1998; 13:315-319.
48. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, et al. Critical evalu¬ation of plasma and LDL oxidant-trapping potential in hemodi-alysis patients. Kidney Int 1999; 56:747-753.
49. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "Antioxidant Power": The FRAP assay. Anal Bi-
ochem 1996; 239:70-76.
50. Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Oxi-dants and antioxidants in atherogenesis: an appraisal. J Lipid Res
1999; 40:2143-2157.
51. Shoji T, Nishizawa Y, Kawagishi T, et al. Atherogenic lipoprote-
in changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis
1997; 131: 229-236.
52. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous mo¬nitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6:67-75.
53. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, Canteloup S, Kebede M. Oxidized low-density lipoprotein induces macropha-ge respiratory burst via its protein moiety: a novel pathway in atherogenesis. Bichem Biophys Res Commun 1999; 263: 804-809.
54. Kaneda H, Taguchi J, Ogasawara K, Lizawa T, Ohna M. Increased level of advanced oxidation protein products in patients with co¬ronary artery disease. Atherosclerosis 2002; 162:221-225.
55. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxida-se and reactive nitrogen species. Arterioscler Thromb Vasc Biol
2000; 20:1716-1723.
56. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated athe¬rosclerosis. Kidney Int 1994; 45:876-883.
57. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascu¬lar disease in chronic renal disease. J Am Soc Nephrol 1998; 9:
916-923.
58. Kitiyakara C, Gonin J, Massy Z, Wilcox CS. Non-traditional cardi¬ovascular disease risk factors in end-stage renal disease: oxidati-ve stress and hyperhomocysteinemia. Curr Opin Nephrol Hyper-
tens 2000; 9:477-487.
59. Inose K, Ono K, Tsutida A. Active inhibitory effect of nafamostat mesylate against the evaluation of plasma myeloperoxidase du¬ring hemodialysis. Nephron 1997; 75:420-425.
60. Ward RA, Ouseph R, McLeish KR. Effects of high-flux hemodialy-sis on oxidant stress. Kidney Int 2003; 63:353-359.
61. Wlodek PJ, Kurcharczyk J, Sokolovska MM, et al. Alteration in plasma levels of nonprotein sulfhydryl compounds and S-nitro-sothiols in chronic renal failure patients. Clin Chim Acta 2003;
327:87-94.
62. Nagase S, Aoyagi K, Hirayama A, et al. Favorable effect of hemo-dialysis on decreased serum antioxidant activity in hemodialysed patients demonstrated by electron spin resonance. J Am Soc
Nephrol 1997; 8:1157-1163.
63. Witko-Sarsat V, Gausson V, Nguyen AT, et al. AOPP-induced ac¬tivation of human neutrophil and monocyte oxidative metabo¬lism: a potential target for N-acetylcysteine treatment in dialysis
patients. Kidney Int 2003; 64:82-91.

Thank you for copying data from http://www.arastirmax.com